Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022

Lamprini Veneti, Jacob Dag Berild, Sara Viksmoen Watle, Jostein Starrfelt, Margrethe Greve-Isdahl, Petter Langlete, Håkon Bøås, Karoline Bragstad, Olav Hungnes, Hinta Meijerink
doi: https://doi.org/10.1101/2022.03.24.22272854

Article usage

Article usage: March 2022 to November 2024

AbstractFullPdf
Mar 2022197818329
Apr 202269620252
May 202227413178
Jun 2022293665
Jul 2022285568
Aug 2022223347
Sep 2022161216
Oct 2022203738
Nov 20221671217
Dec 2022106118
Jan 2023120016
Feb 2023103140
Mar 2023144422
Apr 2023128124
May 20236728
Jun 20237148
Jul 20235719
Aug 2023951015
Sep 20233584190
Oct 20234153125
Nov 2023408142
Dec 20236928
Jan 202483010
Feb 202444310
Mar 202457019
Apr 202462213
May 20247057
Jun 20246028
Jul 202477121
Aug 202479513
Sep 2024661015
Oct 20246068
Nov 202454510
Back to top
Posted March 25, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022
Lamprini Veneti, Jacob Dag Berild, Sara Viksmoen Watle, Jostein Starrfelt, Margrethe Greve-Isdahl, Petter Langlete, Håkon Bøås, Karoline Bragstad, Olav Hungnes, Hinta Meijerink
medRxiv 2022.03.24.22272854; doi: https://doi.org/10.1101/2022.03.24.22272854
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area